NSABP Biospecimen Discovery Project



Status:Recruiting
Conditions:Breast Cancer, Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - Any
Updated:4/21/2016
Start Date:July 2013
End Date:February 2020
Contact:Diana Gosik, RN, BS
Email:diana.gosik@nsabp.org
Phone:412-339-5333

Use our guide to learn which trials are right for you!

This study is a biospecimen discovery project that will serve as a pilot for a comprehensive
'omics approach using fresh core biopsy tissue and blood samples for DNA and protein
analysis, as well as paired tumor-normal exome DNA and RNA sequencing.

This study will be conducted at select NSABP sites where investigators are willing to give
paclitaxel plus trastuzumab or a trastuzumab/pertuzumab-based combination as the initial
component of neoadjuvant therapy as a pilot for a comprehensive 'omics approach using next
generation sequencing and protein expression and post-translational modification analysis
using mass spectrometry (MS) based and Reverse Phase Protein Array-based proteomics. Tumor
samples will be obtained at baseline and 48 to 72 hours after initial drug treatment to
study variation in the biological responses to these agents. The study of tumors both before
and early after the first treatment probes the biological responses to treatment and is rich
source of predictive biomarkers.

Inclusion Criteria:

- The diagnosis of invasive adenocarcinoma of the breast must have been made by core
needle biopsy or limited incisional biopsy.

- The breast cancer must be HER2-positive based on current ASCO/CAP (American Society
of Clinical Oncology/College of American Pathologists) Guideline Recommendations for
Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer.

- The patient must have a mass in the breast measuring greater than or equal to 2.0 cm
by physical exam and/or ultrasound that is accessible and safe for repeat biopsy.
Patients with a diagnosis of inflammatory breast cancer are eligible if there is a
palpable or detectable breast mass that is accessible and safe for repeat biopsy.

- Planned initial treatment with a combination of paclitaxel and trastuzumab or a
trastuzumab/pertuzumab-based combination. Schedule for paclitaxel/trastuzumab or
trastuzumab/pertuzumab administration is per the investigator.

Exclusion Criteria:

- Excisional biopsy or lumpectomy performed prior to registration.

- Previous therapy with chemotherapy or targeted therapy for any malignancy.

- Treatment, including radiation therapy (RT), chemotherapy, and/or targeted therapy,
administered for the currently diagnosed breast cancer prior to registration.

- Other nonmalignant systemic disease that would preclude the patient from receiving
chemotherapy and targeted therapy.
We found this trial at
4
sites
320 E North Ave
Pittsburgh, Pennsylvania 15212
(412) 359-3131
Principal Investigator: Thomas Julian, MD
Allegheny General Hospital At Allegheny General Hospital, our physicians and healthcare staff have earned an...
?
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Gainesville, Florida 32610
(352) 392-3261
Principal Investigator: Carmen Allegra, MD
University of Florida The University of Florida (UF) is a major, public, comprehensive, land-grant, research...
?
mi
from
Gainesville, FL
Click here to add this to my saved trials
1200 Moursund Street
Houston, Texas 77030
(713) 798-4951
Principal Investigator: Mothaffar Rimawi, MD
Baylor College of Medicine Baylor College of Medicine in Houston, the only private medical school...
?
mi
from
Houston, TX
Click here to add this to my saved trials
St Louis, Missouri 63108
Principal Investigator: Adel Tabchy, MD
?
mi
from
St Louis, MO
Click here to add this to my saved trials